Joint (NASDAQ:JYNT – Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02, Zacks reports. Joint had a net margin of 4.81% and a return on equity of 20.96%. The company had revenue of $13.55 million for the quarter, compared to analyst estimates of $14.85 million.
Here are the key takeaways from Joint’s conference call:
- 2026 sales outlook was lowered: The Joint now expects system-wide sales of $508 million–$512 million and comps of negative 3.5% to negative 2.5%, citing continued pressure on consumer spending. Adjusted EBITDA guidance was maintained at $12.5 million–$13.5 million.
- Profitability from continuing operations improved: Third-quarter revenue rose 1% to $13.6 million, net income increased to $1.5 million from $290,000, and Adjusted EBITDA grew to $2.3 million from $1.4 million, reflecting the benefits of the capital-light franchisor model.
- Membership trends strengthened, but have not yet lifted comps: Active members per clinic, conversion, retention, and patient lifetime value improved, aided by flexible membership plans and lapsed-patient outreach. Lower monthly spending per patient—management estimated about $2 of dilution—offset some of those gains.
- Newer clinics are showing stronger economics: Management said recent 2026 openings have taken about three months on average to break even, versus roughly 18 months historically, attributing the improvement to stricter site selection, stronger operators, and pre-opening marketing requirements.
- Clinic closures and cash outflow remain considerations: The company expects year-end clinic count to be about 50 below 2025 as it closes underperforming locations, though it expects to resume clinic growth in 2027. Third-quarter operating cash flow was negative $128,000 and free cash flow was negative $509,000, including a $1.5 million legal-settlement payment.
Joint Stock Down 7.1%
Shares of Joint stock traded down $0.52 on Friday, reaching $6.85. The company’s stock had a trading volume of 151,146 shares, compared to its average volume of 49,725. The company has a market capitalization of $96.86 million, a P/E ratio of 34.25 and a beta of 1.16. The stock has a 50-day moving average price of $7.66 and a 200-day moving average price of $8.53. Joint has a 52-week low of $6.63 and a 52-week high of $10.67.
Key Stories Impacting Joint
Here are the key news stories impacting Joint this week:
- Positive Sentiment: JYNT reported third-quarter EPS of $0.10, up from $0.02 a year earlier and above the $0.08 consensus cited by MarketBeat. The company also expects 2026 system-wide sales of $508 million to $512 million. MarketBeat earnings report 2026 sales outlook
- Neutral Sentiment: Revenue was $13.55 million, up 1% year over year. The company is targeting a comparable-sales turnaround, but the available reports do not provide details on the timing or expected pace of recovery. Third-quarter results and franchise transition
- Negative Sentiment: Revenue fell short of the cited analyst expectation of $14.85 million. EPS estimates differed across sources: although the result beat MarketBeat’s $0.08 consensus, Zacks reported it missed its $0.11 estimate. The revenue shortfall and need to turn around comparable sales may temper investor confidence, particularly amid a challenging consumer environment. Zacks earnings estimates report
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Joint from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Weiss Ratings cut Joint from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, October 26th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.
Read Our Latest Report on JYNT
Joint Company Profile
The Joint Corp. (NASDAQ: JYNT) is a healthcare services company that operates The Joint Chiropractic, a network of chiropractic clinics in the United States. The company focuses on providing routine chiropractic care intended to support musculoskeletal health, mobility and general wellness.
The Joint Chiropractic clinics offer services such as chiropractic adjustments and related wellness care. The business model is designed to provide convenient, accessible care through walk-in visits, membership plans and prepaid packages, with an emphasis on transparent pricing and extended operating hours.
Further Reading
- Five stocks we like better than Joint
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.
